Latest DPCO Price List

Vibcare Pharma

05/03/19

[vc_row][vc_column][ultimate_heading main_heading="Latest DPCO Price List by the Government"][/ultimate_heading][/vc_column][/vc_row][vc_row][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-01.pdf" title="dpco price list nov 2018 01"][/vc_column_text][/vc_column][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-02.pdf" title="dpco price list nov 2018 02"][vc_row][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-03.pdf" title="dpco price list nov 2018 03"][/vc_column_text][/vc_column][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-04.pdf" title="dpco price list nov 2018 04"][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-05.pdf" title="dpco price list nov 2018 05"]2nd November 2018

ORDER

S.O. 5633(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table hereinbelow as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column

(2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Dimercaprol	Injection 50 mg/ml	1 ml	187.85
2.	Phytomenadione (Vitamin K1)	Tablet 10mg	1 Tablet	13.63
3.	Paracetamol	Oral Liquid 100 mg/ml (pediatric)	1 ml	1.52

Note:

All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
Where an existing manufacturer of a scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing

the manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

S.O. 5634(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1462(E), dated 2nd April 2018, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Nitrous oxide	Inhalation	Cubic meter	219.29
2.	Oxygen	Inhalation (Medicinal gas)	Cubic Meter	16.47

Note:

All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
Where an existing manufacturer of a scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing

the manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

O. 5635(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table hereinbelow passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column

of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table hereinbelow as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as specified in the corresponding entries in columns (3), (4) and (8) thereof;

Table

Sl. No.	Name of the Formulation	Dosage form & Strength	Unit	Retail Price (Rs.)	Review Order number and date	Existing SO number & date	Manufacturer & Marketing Company respectively
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1.	Ramipril + Amlodipine Tablet	Each uncoated tablet contains: Ramipril IP 5mg Amlodipine Besylate IP eq. to Amlodipine 5mg	1 Tablet	12.04	31015/2/2018- Pricing dated 08.6.2018	3915(E) dated 18.12.2017 (at Sl. No. 12)	M/s Lupin Limited
2.	Ferrous Ascorbate + Folic Acid + Cyanocobalamin + Zinc Sulphate Monohydrate tablet (Autrin- XT)	Each film coated tablet contains: Ferrous Ascorbate eq. to Elemental Iron 100mg, Folic Acid IP 1.5mg, Cyanocobalamin IP 15 mcg, Zinc Sulphate Monohydrate IP eq. to Elemental Zinc 22.5mg	1 Tablet	8.01	31015/8/2018- Pricing dated 22.06.2018	3915(E) dated 18.12.2017 (at Sl. No. 1)	M/s Tirupati Medicare Limited / M/s Pfizer Limited
3.	Amlodipine + Valsartan Tablet (Valembic 80 AM)	Each film coated tablet contains: Amlodipine Besylate eq. to Amlodipine USP 5mg, Valsartan USP 80mg	1 Tablet	5.56	31015/25/2018- Pricing dated 06.08.2018	793(E) dated 23.02.2018 (at Sl. No. 1)	M/s Vapicare pharma Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited
4.	Amlodipine + Valsartan Tablet (Valembic 160 AM)	Each film coated tablet contains: Amlodipine Besylate eq. to Amlodipine USP 5mg, Valsartan USP 160mg	1 Tablet	8.56	31015/25/2018- Pricing dated 06.08.2018	793(E) dated 23.02.2018 (at Sl. No. 2)	M/s Vapicare pharma Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited
5.	Olmesartan + Amlodipine + Chlorthalidone Tablet (Triolmezest CH 20)	Each film coated tablet contains: Olmesartan IP 20mg Amlodipine Besylate IP eq. to Amlodipine 5mg Chlorthalidone IP – 12.5mg	1 Tablet	9.15	31015/37/2018- Pricing dated 04.09.2018	2398(E) dated 12.6.2018 (at Sl. No. 10)	M/s Synokem Pharmaceuticals Ltd. / M/s Sun Pharma Laboratories Ltd.
6.	Olmesartan +	Each film coated tablet	1	16.19	31015/37/2018-	2398(E)	M/s Synokem

	Amlodipine + Chlorthalidone Tablet (Triolmezest CH 40)	contains: Olmesartan IP 40mg Amlodipine Besylate IP eq. to Amlodipine 5mg Chlorthalidone IP – 12.5mg	Tablet		Pricing dated 04.09.2018	dated 12.6.2018 (at Sl. No. 11)	Pharmaceuticals Ltd. / M/s Sun Pharma Laboratories Ltd.
7.	Rosuvastatin +	Each film coated tablet	1	11.43	31015/37/2018-	2398(E)	M/s Pure and Cure
	Clopidogrel	contains:	Tablet		Pricing dated	dated	Healthcare Pvt. Ltd.
	Tablet (ROSUVAS	Rosuvastatin Calcium IP eq.			04.09.2018	12.6.2018	/ M/s Sun
	CV 10)	to Rosuvastatin 10mg,				(at Sl. No. 9)	Pharmaceutical
		Clopidogrel Bisulfate IP eq.					Industries Ltd
		to Clopidogrel 75mg

Note:

The manufacturer of above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table
The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said
The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act,

2nd November 2018

ORDER

S.O. 5636(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table hereinbelow passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table hereinbelow as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Review Order number and date	Existing SO number and date
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1.	Anti-Tetanus	250IU	Each Pack	1043.05	31015/29/2017-PI.I	1461(E) dated
	Immunoglobulin				dated 6.8.2018	2.04.2018
						(at Sl. No. 60)
						Read with
						corrigendum SO
						2400(E) dated
						12.6.2018

Note:

All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,
The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

O. 5638(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table hereinbelow as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg Metformin Hydrochloride IP 1000 mg (SR)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Anthem Biopharma Pvt. Ltd.	10.23
2.	Metformin HCL + Glimepiride Tablet (Semi Amaryl M)	Each uncoated bilayer tablet contains: Metformin Hydrochloride IP (in prolonged release form) 500 mg Glimepiride IP 0.5 mg	1 Tablet	M/s Windlass Biotech Pvt. Ltd. / M/s Sanofi India Ltd.	3.77
3.	Telmisartan + Cilnidipine + Chlorthalidone tablet	Each film coated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 6.25 mg Cilnidipine IP 10 mg	1 Tablet	M/s Windlass Biotech Pvt. Ltd / M/s Abbott Healthcare Pvt. Ltd	10.31
4.	Clarithromycin for Oral Suspension	Each 5ml (after reconstitution) contains: Clarithromycin IP 250mg, Titanium Dioxide IP (-).	1 ML	M/s Cipla Limited	5.49
5.	Telmisartan + Amlodipine + Chlorthalidone Tablet (Telmelife 3D)	Each film coated tablet contains: Telmisartan IP 40 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg Chlorthalidone IP 12.5 mg	1 Tablet	M/s Akums Drugs & pharmaceuticals Ltd / M/s Neomac Pharmaceuticals Pvt. Ltd	8.91
6.	Atorvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin (As film coated tablet) 20 mg Clopidogrel Bisulphate IP eq. to Clopidogrel (as two film coated tablet each containing 37.5mg) 75 mg	1 Capsule	M/s Windlas Biotech Ltd. / M/s Abbott Healthcare Pvt. Ltd.	9.50
7.	Amoxycillin + Potassium Clavulante	Each uncoated dispersible tablet contains:	1 Tablet	M/s Saitech Medicare Pvt. Ltd. / M/s Galpha	7.45

	tablet (Clanoxy DT)	Amoxycillin Trihydrate eq. to Amoxycillin 200mg Potassium Clavulante Diluted IP eq. to Clavulanic Acid 28.5mg		Laboratories Ltd.
8.	Tramadol + Paracetamol Tablet (Trson-P)	Each film coated tablet contains: Tramadol Hydrochloride IP 37.5 mg Paracetamol IP 325 mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	2.49
9.	Voglibose + Metformin Tablet (Voglyson-M 0.3)	Each uncoated bilayered tablet contains: Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg (as sustained release form)	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	3.86
10.	Rosuvastatin + Aspirin + Clopidogrel Capsules	Each hard gelatin capsules contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10 mg (as pellets) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd.	11.62
11.	Mycophenolate Mofetil Oral Suspension IP	Each 5 ml of reconstituted suspension contains: Mycophenolate Mofetil IP 1 g, (1 bottle with 110gm powder for oral suspension containing 35gm Mycophenolate Mofetil)	Each Pack	M/s Panacea Biotec Ltd.	5238.09
12.	Bisacodyl Suppository	Each Suppository contains: Bisacodyl IP 10 mg	1 Suppository	M/s Meridian Enterprises Pvt. Ltd.	18.63
13.	Telmisartan + Chlorthalidone Tablet (Telmelife CH 40)	Each film coated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg	1 Tablet	M/s Akum Drugs & Pharmaceuticals Ltd. / M/s Neomac Pharmaceuticals Pvt. Ltd.	8.00
14.	Cilnidipine + Telmisartan Tablet	Each film coated tablet contains: Telmisartan IP 80 mg Cilnidipine 10 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	10.60
15.	Divalproex Tablet (Diwok OD 750 mg)	Each film coated extended release tablet contains: Divalproex Sodium IP eq. to Valproic Acid 750 mg	1 Tablet	M/s Swiss Garnier Biotech / M/s Wockhardt Ltd.	11.24
16.	Clotrimazole + Beclomethasone Dipropionate Cream	Cream contains: Clotrimazole IP 1.00% w/w Beclomethasone Dipropionate IP 0.025% w/w	1 GM	M/s Curetech Skincare / M/s Mankind Pharma Ltd.	4.46
17.	Telmisartan + Chlorthalidone Tablet (Cresar CT)	Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 6.25 mg	1 Tablet	M/s Acme Formulations Pvt. Ltd. / M/s Cipla Ltd.	7.71
18.	Baclofen Oral Solution	Each 5 ml contains: Baclofen IP 5 mg	1 ML	M/s Sun Pharmaceutical Industries Ltd. / M/s Sun Pharma Laboratories Ltd.	1.42
19.	Glimepiride + Metformin Hydrochoride Tablet	Each uncoated bilayered tablet contains: Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 3 mg	1 Tablet	M/s Sun Pharma Laboratories Ltd.	6.99
20	Glimepiride + Metformin Hydrochoride Tablet	Each uncoated bilayered tablet contains: Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 4 mg	1 Tablet	M/s Sun Pharma Laboratories Ltd.	8.58

21.	Glimepiride + Metformin Hydrochoride Tablet	Each uncoated bilayered tablet contains: Metformin Hydrochoride IP (as prolonged release) 1000mg Glimepiride IP 4 mg	1 Tablet	M/s Sun Pharma Laboratories Ltd.	9.78
22.	Metformin HCL + Gliclazide + Pioglitazone Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 30 mg Pioglitazone HCL eq. to Pioglitazone 15 mg	1 Tablet	M/s Eris Lifesciences Ltd.	5.78
23.	Metformin HCL + Gliclazide + Pioglitazone Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 60 mg Pioglitazone HCL eq. to Pioglitazone 15 mg	1 Tablet	M/s Eris Lifesciences Ltd.	8.29
24.	Chlorthalidone + Telmisartan Tablet (Telsar CH 40/6.25)	Each film coated tablet contains: Chlorthalidone IP 6.25 mg Telmisartan IP 40 mg	1 Tablet	M/s Gkm New Pharma / M/s Torrent Pharmaceuticals Ltd.	7.71
25.	Chlorthalidone + Telmisartan Tablet (Telsar CH 40/12.5)	Each film coated tablet contains: Chlorthalidone IP 12.5mg Telmisartan IP 40 mg	1 Tablet	M/s Gkm New Pharma / M/s Torrent Pharmaceuticals Ltd.	8.03
26.	Chlorthalidone + Telmisartan Tablet (Telsar CH 80/12.5)	Each film coated tablet contains: Chlorthalidone IP 12.5mg Telmisartan IP 80 mg	1 Tablet	M/s Gkm New Pharma / M/s Torrent Pharmaceuticals Ltd.	13.91
27.	Divalproex Tablet (Diwok OD 250 mg)	Each film coated extended release tablet contains: Divalproex Sodium IP eq. to Valproic Acid 250 mg	1 Tablet	M/s Swiss Garnier Biotech / M/s Wockhardt Ltd.	5.45
28.	Voglibose + Metformin tablet	Each uncoated tablet contains: Voglibose IP 0.2 mg Metformin HCL IP 500 mg	1 Tablet	M/s Eris Lifesciences Ltd.	6.57
29.	Amoxycillin + Potassium Clavulnate Dry Syrup (Blumox-CA Forte)	Each combipack containing: a) Amoxycillin and Potassium Clavulanate Oral Suspension IP Each 5 ml suspension containing Amoxycillin Trihydrate IP eq. to Amoxycillin 400 mg Potassium Clavulnate diluted IP eq. to Clavulanic Acid 57 mg b) 1 vial sterile water for injection IP Each vial containing Sterile water for injection IP 30 ml	1 ML	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	3.16
30.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20 mg (as pellets) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	17.88
31.	Rosuvastatin + Aspirin + Clopidogrel	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Emcure	11.62

	Capsule	Aspirin IP 75mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as pellets)		Pharmaceuticals Ltd.
32.	Diclofenac + Virgin Linseed Oil + Methyl Salicylate + Menthol + Capsaicin Gel (Diclofam Hot)	Gel containing Diclofenac Diethylamine BP 1.16% w/w (eq. to Diclofenac Sodium 1% w/w) Virgin linseed Oil BP 3% w/w (containing predominantly Alpha Linolenic Acid) Methyl Salicylate IP 10% w/w Menthol IP 5% Capsaicin USP 0.0255w/w, Benzyl Alcohol IP 1%w/w	1 GM	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd.	2.41
33.	Clotrimazole + Lignocaine Ear Drops (Triben)	Ear drops contains: Clotrimazole IP 1.0% w/v Lignocaine Hydrochloride IP 2.0% w/v	1 ML	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Jenburkt Pharmaceuticals Ltd.	5.27
34.	Timolol + Brinzolamide Eye Drops	Each ml contains Brinzolamide IP 1.0 w/v Timolol Maleate IP eq. to Timolol 0.5% w/v, Benzalkonium Chloride IP 0.01% w/v (as preservative)	5ML	M/s Ajanta Pharma Ltd.	283.25
35.	Diclofenac + Methyl + Menthol GEL (Volini Maxx Gel)	Contains: Diclofenac Diethylamine BP 2.32% w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w	Each Pack (20 gram)	M/s Sun Pharmaceutical Industries Ltd.	125.00
36.	Diclofenac + Methyl + Menthol GEL (Volini Maxx Gel)	Contains: Diclofenac Diethylamine BP 2.32% w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w	Each Pack (30 gram)	M/s Sun Pharmaceutical Industries Ltd.	187.50
37.	Olmesartan + Amlodipine + Chlorthalidone Tablet (TRIOLSAR 20)	Each film coated tablet contains: Olmesartan Medoxomil 20mg, Chlorthalidone IP 6.25mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets	1 Tablet	M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited	9.585
38.	Olmesartan + Amlodipine + Chlorthalidone Tablet (TRIOLSAR 40)	Each film coated tablet contains: Olmesartan Medoxomil 40mg, Chlorthalidone IP 6.25mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets	1 Tablet	M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited	15.61

39.	Losartan + Chlorthalidone + Amlodipine Tablet (TRILOSAR 6.25 )	Each film coated tablet contains: Losartan Potassium IP 50mg, Chlorthalidone IP 6.25mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets	1 Tablet	M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited	6.36
40.	Losartan + Chlorthalidone + Amlodipine Tablet (TRILOSAR 12.50)	Each film coated tablet contains: Losartan Potassium IP 50mg, Chlorthalidone IP 12.50mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets	1 Tablet	M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited	6.41
41.	Darunavir + Ritonavir tablet	Each film coated tablet contains: Darunavir Ethanolate eq. to Darunavir 600mg and Ritonavir IP 100mg tablet	1 Tablet	M/s Emcure Pharmaceuticals Limited	172.52
42.	Telmisartan + Amlodipine + Chlorthalidone Tablet (Tazloc AC 12.5)	Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg Chlorthalidone IP 12.5 mg	1 Tablet	M/s Aeon Formulations Pvt. Ltd. / M/s USV Pvt. Ltd.	8.91
43.	Darunavir + Ritonavir tablet (Durart – R 450)	Each film coated tablet Contains: Darunavir 400mg & Ritonavir 50mg Tablets	1 Tablet	M/s Mylan Laboratories Pvt. Ltd. / M/s Mylan Pharmaceuticals Pvt. Ltd.	123.71
44.	Diclofenac + Methyl + Menthol Salicylate + Menthol + Turpentine Oil Gel (Diclotal MR Gel)	Contains: Diclofenac Diethylamine BP 1.16%w/w (eq. to Diclofenac Sodium 1%), Methyl Salicylate IP 5% w/w, Mephenesin IP 85 5%w/w, Menthol IP 2% w/w, Turpentine Oil BP 3%w/w	1 GM	M/s The Madras Pharmaceuticals / M/s Blue Cross Laboratories Pvt. Ltd.	2.46
45.	Lamivudine + Tenofovir + Dolugetravir tablet	Each film coated tablet contains: Lamivudine IP 300mg, Tenofovir Disoproxil Fumarate IP 300mg eq. to Tenofovir Disoproxil 245mg, Dolugetravir Sodium eq. to Dolutegravir 50mg.	1 Tablet	M/s Emcure Pharmaceuticals Limited	114.06
46.	Darunavir + Ritonavir tablet (Danavir R)	Each film coated tablet contains: Darunavir Ethanolate eq. to Darunavir 800mg, Ritonavir 100mg Tablet	1 Tablet	M/s Hetero Labs Limited / M/s Hetero Healthcare Limited	212.91
47.	Lamivudine + Tenofovir + Dolugetravir tablet (ACRIPTEGA)	Each uncoated tablet contains: Lamivudine IP 300mg, Tenofovir Disoproxil Fumarate IP 300mg, Dolugetravir Sodium eq. to Dolutegravir 50mg.	1 Tablet	M/s Mylan Laboratories Limited / M/s Mylan Pharmaceuticals Private Limited	114.06

48.	Daclatasvir + Sofosbuvir tablet (HEPCINAT PLUS)	Each film coated tablet contains: Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg	1 Tablet	M/s Natco Pharma Limited	556.442
49.	Daclatasvir + Sofosbuvir tablet	Each film coated tablet contains: Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg	1 Tablet	M/s Natco Pharma Limited / M/s Cadila Healthcare Limited	556.442
50.	Daclatasvir + Sofosbuvir tablet (MYHEP DVIR)	Each film coated tablet contains: Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg	1 Tablet	M/s Mylan Laboratories Pvt. Ltd. / M/s Mylan Pharmaceuticals Pvt. Ltd.	556.442
51.	Diclofenac + Methyl + Menthol GEL (Volini Maxx Gel)	Contains: Diclofenac Diethylamine BP 2.32% w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salicylate IP 10% w/w & Menthol IP 5% w/w	Each Pack (15 gram)	M/s Sun Pharmaceutical Industries Ltd.	93.75
52.	Diclofenac + Methyl + Menthol GEL (Volini Maxx Gel)	Contains: Diclofenac Diethylamine BP 2.32% w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w	Each Pack (10 gram)	M/s Sun Pharmaceutical Industries Ltd.	62.50
53.	Ceftriaxone 1 gm plus Tazobactum 125 mg injection	Each injection vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 1 gm Tazobactum Sodium eq. to Tazobactum 125 mg	1 Vial	M/s Innova Captab Pvt. Ltd. / M/s Emcure Pharmaceuticals Ltd	136.11
54.	Cefpodoxime + Potassium Dry Syrup (Cefoprox CV)	Each 5 ml of the reconstituted suspension contains: Cefpodoxime Proxetil IP eq. to Cefpodoxime 50 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 31.25 mg	1 ML	M/s Hetero Labs Ltd / M/s Cipla Limited	2.40
55.	Cefpodoxime + Potassium Dry Syrup (Cefoprox CV)	Each 5 ml of the reconstituted suspension contains: Cefpodoxime Proxetil IP eq. to Cefpodoxime 100 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 62.5mg	1 ML	M/s Hetero Labs Ltd / M/s Cipla Limited	3.72

Note:

The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table

The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said
The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act,
Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

DPCO Price List - March 2019